Soluble forms of ICAM-1, VCAM-1, E-selectin, L-selectin, P-selectin and, more recently, ICAM-3 are known to exist in human serum and have elevated levels in numerous diseases. Previous studies have demonstrated that in rheumatoid arthritis (RA) the levels of circulating sICAM-1, sVCAM-1 and sE-selectin are elevated relative to healthy controls. We have compared the serum profiles of these six soluble adhesion molecules in patients with RA (n = 22) to those seen in healthy controls (n = 10) using sandwich ELISA. In the patients, there were significant elevations of serum sICAM-1 (P Q 0.0001), sICAM-3 (P = 0.0327), sVCAM-1 (P = 0.0025), sL-selectin (P = 0.0194) and sP-selectin (P = 0.0025), but not E-selectin (P = 0.0672). However, only sP-selectin was found to correlate with disease activity in the patients (r = 0.461, P Q 0.05). Thus, there is a distinct profile of soluble adhesion molecules in RA of which only sP-selectin correlates with disease activity.
A  of cell adhesion molecules have been detected as soluble circulating forms (sCAM) in human serum and other body fluids. These include the selectins [E (CD62E), L (CD62L) and P (CD62P)] [1] [2] [3] and members of the immunoglobulin superfamily, namely PECAM-1 (CD31) [4] , VCAM-1 (CD106) [5] and ICAM-1 (CD54) [6, 7] and, more recently, ICAM-3 (CD50) [8] [9] [10] .
The expression of the majority of these cell adhesion molecules seems to be upregulated or induced by cytokines. Several agonists [tumour necrosis factor-alpha (TNF-a) and interleukin (IL)-1] induce de novo expression of VCAM-1 and E-selectin and upregulation of ICAM-1 on vascular endothelium in vitro. P-selectin is expressed on activated endothelial cells and platelets by rapid release from Weibel-Palade bodies and a granules, respectively (reviewed in [11] ). ICAM-1 expression is also upregulated from low basal levels by cytokine activation of leucocytes and fibroblasts [12, 13] . L-Selectin and ICAM-3 are constitutively expressed on the surface of most resting leucocytes, but not endothelium [14] [15] [16] [17] . More recently, Langerhans cells in the epidermis have been found to express ICAM-3 constitutively [18] .
Cultured endothelial cells that have been cytokine activated release sICAM-1, sVCAM-1 and sE-selectin [1, 19] , and sCAM-1 is also released from mononuclear cells induced to express ICAM-1 at their surface [7] . L-Selectin is rapidly shed via proteolytic cleavage following leucocyte activation [2, 20, 21] , whereas P-selectin is released from activated platelets as a secreted form lacking a transmembrane domain [3] . The levels of adhesion molecules detectable as soluble forms have been studied in numerous disease states [22] , including rheumatoid arthritis (RA) in which both sICAM-1 and sVCAM-1 have been detected at elevated levels compared with normal controls in the plasma, sera and synovial fluid [5, 23, 24] . In contrast, patients with systemic lupus erythematosus (SLE) had raised sVCAM-1, but not sICAM-1 levels in plasma [5, 23] . More recently, the expression of L-selectin on neutrophils isolated from synovial fluid of patients with inflammatory joint diseases, including RA, has been found to be reduced compared to peripheral blood neutrophils and is similar to that observed on in vitro N-formyl methionyl peptide (FMLP)-activated neutrophils. However, sL-selectin was detected at similar levels in synovial fluid and peripheral blood of RA patients, and was not elevated relative to normal controls [25] .
On resting lymphocytes, ICAM-3 is the dominant ligand for LFA-1 (a b2 leucocyte integrin) and, since the expression of ICAM-3 mRNA is highest in T cells and in cell types implicated in antigen presentation to T cells, ICAM-3 may be important in the generation of immune responses [15, 26] . A soluble form of ICAM-3 has recently been detected in the circulation of healthy individuals [8] [9] [10] and levels are elevated in certain immune-mediated diseases (RA, Guillain-Barre´syn-drome, multiple sclerosis and SLE) [9, 10] . Here, we describe the detection and quantitation of six soluble adhesion molecules, including P-and L-selectin, in sera Correspondence to: D. L. Simmons, Cell Adhesion Lab., ICRF, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DU. from healthy human volunteers and patients with RA. Our findings reveal that there is a distinct profile of elevated soluble adhesion molecules in individuals affected with RA.
PATIENTS AND METHODS

Subjects
We studied 22 patients (age range 29-77 yr, mean 57 2 12.6 yr), all of whom fulfilled the 1987 American College of Rheumatology criteria for RA. The majority of these patients (18/22) had suffered from RA for at least 5 yr. All had been treated with slow-acting anti-rheumatic drugs during the preceding 5 yr; however, at the time of examination, five of the patients were taking sulphasalazine, three azathioprine, four i.m. gold, six low-dose methotrexate and the remaining four others combinations of other slow-acting antirheumatic drugs including prednisolone. All patients had erosive disease and were rheumatoid factor positive. Blood was taken by venepuncture from these RA patients and 10 healthy individuals (age range 20-52 yr, mean 35.6 2 9.4 yr) and allowed to clot for 5 min on ice before centrifugation and storage of serum at −20°C. Disease activity in the RA patients was assessed by measurement of the erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP), and leucocyte counts were obtainted from samples taken at the same time.
Monoclonal antibodies
Mouse monoclonal antibodies (mAbs) CAL3.10 and CAL3.34 directed against extracellular domains 1 and 4 of ICAM-3, respectively, were prepared as previously described [27] . CAL3.34 was coupled to horseradish peroxidase by periodate treatment [28] . Other mAbs used as components of the sCAM ELISA kits (R&D Systems Europe Ltd, Abingdon) were: ICAM-1: BBIG-I1, BBIG-I2; E-selectin: BBIG-E4, BBIG-E5; VCAM: BBIG-V3, BBIG-V4; L-selectin: 4G8; P-selectin: 9E7. For L-and P-selectin, rabbit polyclonals conjugated to horseradish peroxidase were used as the detecting mAb.
Chemicals
Unless otherwise stated, all reagents were obtained from Sigma Chemical Company Ltd, Poole.
ELISA for detection and quantitation of soluble ICAM-3
ELISAs were performed with capture and detecting antibodies to domain 1 and 4 of ICAM-3, respectively, thereby ensuring that only forms of sICAM-3 containing at least domains 1-4, and therefore representative of specific membrane cleavage and not non-specific degradation, were detected. The specificity of the assay was ensured by the absence of cross-reactivity with ICAM-1-Fc even when added at 500 ng/ml (data not shown).
Prior to the assay, sera were diluted 1 in 10 in phosphate-buffered saline (PBS), centrifuged for 1 h at 100 000 g and filtered through 0.2 mm filters. Sera treated in this way were subsequently stored in aliquots at −20°C with 0.02% sodium azide. Ninety-six-well Immulon 3 microtitre plates (Dynatech Laboratories, Inc., Virginia, USA) were coated with 50 ml/well of primary capture antibody CAL3.10 at 10 mg/ml in 0.05  carbonate/bicarbonate buffer (pH 9.6) overnight at 4°C. Wells were washed three times with wash buffer [PBS/0.25% bovine serum albumin (BSA)/0.02% azide] and then blocked with 100 ml of PBS/2% BSA for 2 h at room temperature. Wells were washed twice and a titration of FPLC-purified soluble recombinant ICAM-3 standards, containing all five extracellular Ig-like domains and lacking the transmembrane and cytoplasmic domains [ICAM-3(D1-D5)-stop], from 0 to 500 ng/ml in PBS/0.02% sodium azide/10% fetal calf serum and treated serum samples were added (50 ml/well) in triplicate for 2 h at room temperature. Wells were washed three times and 50 ml horseradish peroxidase-conjugated CAL3.34 at 2 mg/ml in PBS/ 4 mg/ml BSA were added to each well for a further 2 h. Wells were finally washed three times before the addition of 100 ml of 0.4 mg/ml o-phenylenediamine dihydrochloride, 0.014% hydrogen peroxide in a 0.05  phosphate-citrate buffer (pH 5). Plates were read on a Multiscan Multisoft plate reader (Labsystems, Finland) at 450 nm within 30 min of substrate addition. Assays were repeated five times with high interassay reproducibility with a standard titration curve of ICAM-3(D1-D5)-stop included in each case.
ELISA for detection and quantitation of soluble VCAM-1, ICAM-1, E-selectin, and L-selectin
ELISA assays were carried out on diluted, treated sera according to the manufacturer's instructions (R&D Systems Europe Ltd, Abingdon). The sensitivity of each of the assays was Q2 ng/ml.
ELISA for detection and quantitation of soluble P-selectin
Soluble P-selectin levels in the treated sera were determined using a sandwich immunoassay calibrated with recombinant human P-selectin. The final sample dilution was 1 in 20 with an assay range of 0-50 ng sP-selectin/ml and a sensitivity of Q0.5 ng/ml.
Lactate dehydrogenase (LDH) assays
LDH assays were performed on sera diluted 1 in 10 with a 0.9% sodium chloride solution in accordance with the manufacturer's instructions (Boehringer Mannheim, Germany).
C-Reactive protein assay and erythrocyte sedimentation rates
CRP protein assays were performed by the Immunology Department, Churchill Hospital, Oxford, and were measured by immunoturbidimetry. ESRs were obtained from medical records.
Statistical analysis
Differences in levels of circulating adhesion molecules between normals and RA patients were tested for significance using a Mann-Whitney U-test.
Correlations between variables were analysed using Spearman's rank-order correlation coefficient (r), where the closer r approaches 1 and −1 the greater is the degree of positive and negative association, respectively. For both statistical methods, P values lower than 0.05 were considered significant.
RESULTS
A distinct profile of soluble adhesion molecules elevated in rheumatoid arthritis
The concentrations of the panel of six soluble adhesion molecules in patients with RA and controls are shown in Fig. 1 . sE-Selectin was the only member not to show a significant elevation in RA.
Previous reports have shown that there is no effect of age on sE-selectin, sVCAM-1 or sICAM-1 levels [1, 5, 23] . In this study, no correlation was found between the age of the healthy donors and the levels of sICAM-1, sICAM-3, sVCAM-1, sE-selectin, sL-selectin or sP-selectin (r E 0.207, not significant for all six sCAMs).
A correlation analysis of sCAM concentrations and platelet counts in sera from RA patients revealed that the only positive correlation existed for sP-selectin (r = 0.601, P Q 0.001), but there was a negative correlation for sL-selectin (r = − 0.76, P Q 0.001) and sVCAM (r = − 0.706, P Q 0.001). However, despite this, only four of the 22 RA patients had platelet counts that exceeded the range expected in a healthy individual (150-450 × 10 9 /l). No association was found between the leucocyte cell count and the concentrations of any of the six sCAMs in the RA patients (r E 0.059, not significant). Total leucocyte counts were used as there is differential expression of the six adhesion molecules on the various leucocyte subsets.
There was a range of disease activity in the RA patients chosen for this study as assessed by clinical examination and by the two most commonly used markers of RA disease activity: CRP and ESR. The relationship between the levels of all sCAMs and ESR (mm/h) and CRP (mg/l) was thefore examined. A significant positive association was obtained only for sP-selectin levels when compared with CRP levels (r = 0.461, P Q 0.05) and ESR (r = 0.496, P Q 0.025). However, neither sICAM-1, sICAM-3, sVCAM-1, sE-selectin nor sL-selectin correlated with either CRP or ESR in the RA group. There was a significant correlation between ESR and CRP levels in the RA patients (r = 0.633, P Q 0.005).
The release of soluble forms of adhesion molecules may be a consequence of cell damage, in particular that arising from cytokine induction in an inflammatory disease such as RA. To investigate this, the activity of LDH (a cytoplasmic enzyme) in serum was monitored as a marker of cell lysis. The majority of RA sera had LDH levels (130-230 U/l) that fell into the normal range expected in serum (120-240 U/l). Two of the 22 RA sera gave LDH activity that was 50-90 U/l greater than the highest value expected for the normal range. These sera, however, did not contain the highest levels of any of the soluble adhesion molecules assayed (data not shown).
The relationship between serum levels of the soluble adhesion molecules
When the serum levels of each soluble cell adhesion molecule (sCAM) were directly compared with levels of another sCAM in the healthy individuals and RA patients, it was found that there were significant positive correlations only between the levels of sICAM-1 and sE-selectin (r = 0.486, P Q 0.025), and sL-selectin and sVCAM-1 (r = 0.675, P Q 0.001). Significant negative correlations were obtained between sP-selectin and sVCAM (r = − 0.491, P Q 0.025), and sP-selectin and sL-selectin (r = − 0.511, P Q 0.025). These positive and negative correlations were only found between sCAMs measured in RA patients (Table I) .
DISCUSSION
Here, we have demonstrated for the first time that there is a distinct pattern of elevation and correlation with disease activity of sICAM-1, sICAM-3, sVCAM-1, sL-selectin, sP-selectin and sE-selectin in the serum of RA patients relative to healthy individuals. The augmented release of these adhesion molecules from endothelial cells and/or leucocytes is not simply the result of increased cell lysis upon cytokine induction as LDH levels in the RA sera were normal. There was no association of soluble adhesin levels with leucocyte counts in the RA patients, indicating that elevated sCAMs do not merely reflect an increase in the leucocyte population. Although there is interindividual variation of sCAMs in the RA patients, it is unlikely that this is due to differences in drug treatment at the time of examination since the use of slow-acting anti-rheumatic drugs was evenly spread in the patient group.
The regulation and kinetics of expression of the cell surface forms of the six sCAMs assessed in this study have been described in detail elsewhere [11] . Interestingly, combinations of cytokines can differentially modulate the induction of ICAM-1, VCAM-1 and E-selectin on endothelium, and of ICAM-1 on other cell types.Therefore, the various patterns of cytokines or inflammatory mediators associated with a particular inflammatory disease may lead to differential induction of endothelial and leucocyte adhesion molecules, which in turn may influence the pathogenesis of the disease. Moreover, since several studies have shown that release of sCAMs in vitro is triggered or augmented by cytokines and other activating regimes, elevated sCAMs may reflect patterns of cytokine production and may enable a profile of elevated sCAMs to be assigned to a disease [1-3, 7, 8, 10, 19-21] .
Many cytokines with inflammatory and destructive properties are detectable in patients with RA. In the activated state, infiltrating and resident cells in the synovium are able to produce large amounts of cytokines such as IL-1a and IL-1b and TNF-a [29] . In rheumatoid synovial cell cultures, anti-TNF-a mAbs diminished the production of pro-inflammatory mediators such as IL-1 and granulocyte-macrophage colony-stimulating factor (GM-CSF) [30, 31] . More recently, in a multicentre, randomized, double-blind placebo-controlled trial, a chimeric mAb to TNF-a suppressed RA disease [32] . Hence, in RA it seems that TNF-a is a dominant cytokine in the network regulating the production of IL-1 and GM-CSF, and consequently is capable of inducing expression of VCAM-1 and E-selectin on endothelium, and ICAM-1 on endothelium and synovial fibroblasts.
To date, the release of CAMs, by secretion or shedding, has been well documented with many reports of elevated levels in disease [22] . In the case of RA and other inflammatory joint diseases, studies have assessed one or several sCAM levels relative to healthy controls. This study provides the first measurement of a panel of six sCAMs in RA.
Previously, a significant positive correlation was found between plasma levels of sVCAM-1 and ESR in RA, with a weaker correlation between sVCAM-1 and CRP, while sICAM-1 did not correlate with either disease marker [23] . Elsewhere, serum levels of sICAM-1 have shown a weak but significant correlation with joint score and ESR in RA patients treated with non-steroidal anti-inflammatory drugs [24] . In this study, we found that only sP-selectin had a significant association with both ESR and CRP. Currently, sP-selectin is the least well studied sCAM and this is the first description of sP-selectin in RA. The other five adhesins showed no relationship with either marker. To date, only in SLE have sICAM-3 levels been found to be significantly raised in active compared with inactive disease [9, 10] .
Surprisingly, despite ICAM-3 being a constitutively expressed leucocyte surface molecule, it is present in normal sera at much lower concentrations than inducible adhesins VCAM-1 and ICAM-1, and even L-selectin, which is also constitutively expressed. Furthermore, the circulating form of sICAM-3 in RA never reaches the absolute levels in ng/ml of sVCAM-1, sICAM-1, sL-selectin or sP-selectin shed in healthy individuals. This difference in absolute levels released and the lack of association between the levels of sICAM-3 and sICAM-1, sVCAM-1, sE-selectin, sL-selectin and sP-selectin in healthy and RA individuals, suggests that distinct mechanisms may exist to regulate the specific release of adhesins.
The mechanism by which sCAMs are released from the cell surface is generally thought to be either by secretion or proteolytic cleavage close to the membrane of surface-expressed forms. Alternative splicing of mRNA generates a soluble secreted form of P-selectin in plasma lacking a transmembrane domain [3] , whereas for L-selectin a membrane-proximal cleavage event at a defined amino acid motif results in rapid shedding from activated leucocytes [2, 33] . The soluble forms of ICAM-1, ICAM-3, VCAM-1 and E-selectin all have sizes consistent with the absence of transmembrane and cytoplasmic domains and, since to date there is no evidence of alternatively spliced mRNA for any of these molecules in humans, proteolytic cleavage seems more likely [1, 5, 7, 8, 10] . Recently, however, a glycolipid-anchored splicing variant of mouse VCAM-1 has been identified which is shed by a mechanism independent of that which causes the release of the transmembrane form [34] . The downregulation of ICAM-3 on neutrophils is blocked by protease inhibitors and there is no downregulation of mRNA in peripheral blood monocytes upon loss of surface expression [8, 10] .
The function of the sCAMs in healthy and RA individuals remains to be established. Both sICAM-1, sVCAM-1, sE-selectin and sP-selectin have previously been found to be capable of supporting leucocyte or cell line adhesion when immobilized onto plastic [1, 3, 5, 7] , and sL-selectin can inhibit lymphocyte binding to cytokine-activated endothelium [2] . sCAMs may be produced as a consequence of inflammation (a 'bystander' effect) or they may function by competing with cell surface forms for ligand, thereby regulating the inflammatory response. Recently, soluble recombinant ICAM-1 blocked the in vitro proliferation of T cells from patients with insulin-dependent diabetes mellitus in response to an islet cell autoantigen [35] . In view of the recent report that soluble forms of E-selectin and VCAM can act as potent angiogenic factors [36] , sCAMs may have a pivotal role in inflammation.
In conclusion, we have found that the levels of sICAM-1, sICAM-3, sVCAM-1, sL-selectin and sP-selectin, but not sE-selectin, were significantly elevated in RA serum compared with serum from healthy donors. Thus, there is a distinct profile of soluble adhesion molecules that are elevated in RA. Moreover, since sP-selectin was found to correlate with disease activity, this cell adhesion molecule may be a useful marker of disease activity in RA and will require careful evaluation in longitudinal studies. A This work was supported by the Imperial Cancer Research Fund, the Wellcome Trust (CB), R&D Systems Europe Ltd (IC) and the MRC (JM).
